European Parliament vote could deter investors from medical device technology
This article was originally published in Clinica
Executive Summary
The regulatory costs for devices that would be hit by the European Parliament's vote to favour the primacy of pharmaceutical legislation over other legislation where there are cases of doubt could be "multiplied drastically". That is the fear of the European medical device industry association, Eucomed, which predicts a negative impact on the pace of development and the consequent downturn on investment in Europe in medical technology manufacturing. That is unless the European Parliament's vote is overturned by the European Council which is due to complete the final reading of the text early in 2004.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.